Rob Steere, VP commercial strategy (CRM) for Veeva Systems, discusses ways to maximize HCP engagement in a post-COVID world.
W2O announced two new products available through Symplur, the company’s social media analytics platform dedicated exclusively to the healthcare industry.
Outcome Health announced the launch of Who Saves Me?, a campaign to bring awareness to the overwhelming percentage of physicians who quietly suffer from burnout and mental health struggles.
In recognition of World Suicide Prevention Day, FCB Health New York announced the launch of “Disappearing Doctors,” a pro bono initiative advocating for and providing mental health support to physicians in need, in partnership with Sermo, Haymarket Media Group and the National Suicide Prevention Lifeline.
Patients do not just want a doctor with a good bedside manner, according to new Everyday Health and Klick Health research exploring the growth of telemedicine and its increasing popularity with patients who continue to have healthcare needs, even in the midst of a pandemic and a socially distanced world.
During this webinar, learn more about benefits and risks of changing primary components during product development and how a design of experiments approach can be used to address issues and risks.
Greater Than One’s Christa Toole analyzes how healthcare marketers are adjusting to the current health crisis in a variety of ways.
Outcome Health announced the OH Virtual Waiting Room, ushering the Point of Care sector into telemedicine with an empathetic, unique patient experience whenever and wherever patients are meeting with their physicians.
New Klick Health research published in Nature Digital Medicine says physicians could get a more comprehensive view of their patients’ health – and even help predict chronic disease early by assessing the interdependence of their health indicators and the body’s homeostasis system that controls them.
As researchers and physicians try to identify ways to effectively treat and prevent COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, some are studying whether high-dose intravenous immunoglobulin (IVIg) could work. IVIg is a common blood plasma product that is used to treat other immune disorders.